Core Insights - Theratechnologies Inc. has resumed distribution of EGRIFTA SV (tesamorelin for injection) after receiving approval from the U.S. FDA for two recently manufactured batches, with immediate shipment to pharmacies [1][2] - The company emphasizes its commitment to providing EGRIFTA SV to individuals with HIV and appreciates the FDA's collaboration in this process [2] - The FDA's review of the Company's Prior Approval Supplement is ongoing, with an action goal date set for April 18, 2025 [2] Company Overview - Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies aimed at redefining standards of care [3] - The company is publicly traded on both the TSX and NASDAQ under the ticker symbols TH and THTX, respectively [3]

Company Overview - Theratechnologies is a biopharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs [2] - The company is publicly traded on the TSX (TH) and NASDAQ (THTX) [2] Product Situation - EGRIFTA SV (tesamorelin for injection) is the only FDA-approved medicine of its kind for people with HIV [1] - A shortage of EGRIFTA SV will occur at the patient level in mid-January 2025 due to a voluntary shutdown of the contract manufacturing facility in 2024 [4] - Some pharmacies in the United States still have remaining inventory, but several have reported stockouts [4] Regulatory Process - Theratechnologies filed a Prior Approval Supplement (PAS) with the FDA on December 18, 2024 [5] - The company submitted questions regarding two recently manufactured batches of EGRIFTA SV waiting to be released [5] - FDA confirmed it will respond to the company's questions in writing by February 8, 2025 [5] Forward-Looking Statements - The company expects FDA to provide answers to its questions by February 8, 2025 [8] - Assumes current market demand for EGRIFTA SV will remain unaffected [8] - Believes the shortage will not adversely impact the company's financial conditions [8] - Anticipates being able to negotiate waivers of defaults with secured creditors if needed [8]

THE WOODLANDS, Texas, Dec. 30, 2024 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality," "Target" or the "Company") (Nasdaq: TH), one of North America's largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced the hiring of Brendan Dowhaniuk as Executive Vice President of Strategy and Corporate Development. Mr. Dowhaniuk will be responsible for advancing the Company's key strategic priorities, including mergers and acquisitions, and f ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that t ...

Target Hospitality Corp. (NASDAQ:TH) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Mark Schuck - SVP, IR Brad Archer - President and CEO Jason Vlacich - CFO and Chief Accounting Officer Conference Call Participants Alec Scheibelhoffer - Stifel Operator Good morning, ladies and gentlemen. And welcome to the Target Hospitality Third Quarter 2024 Earnings Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38343 TARGET HOSPITALITY CORP. (Exact name of registrant as specified in its charter) Delaware 98-1378631 (State or o ...

For the quarter ended September 2024, Target Hospitality (TH) reported revenue of $95.19 million, down 34.8% over the same period last year. EPS came in at $0.20, compared to $0.43 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $87.9 million, representing a surprise of +8.30%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being $0.12.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Target Hospitality (TH) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this company would post earnings of $0.17 per share when it actually produced earnings of $0.18, delivering a surprise of 5.88%.Over the last four quarters, the company ...

Exhibit 99.1 Target Hospitality Reports Impressive Third Quarter 2024 Results Supported by Strong Business Fundamentals THE WOODLANDS, Texas, November 12, 2024 (PRNewswire) – Target Hospitality Corp. ("Target Hospitality", "Target" or the "Company") (NASDAQ: TH), one of North America's largest providers of vertically-integrated modular accommodations and value-added hospitality services, today reported results for the three months ended September 30, 2024. Financial and Operational Highlights ● Revenue of $ ...

Wall Street analysts forecast that Target Hospitality (TH) will report quarterly earnings of $0.12 per share in its upcoming release, pointing to a year-over-year decline of 72.1%. It is anticipated that revenues will amount to $87.9 million, exhibiting a decline of 39.8% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course o ...